Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Anlon Healthcare should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
No Data Found
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
65.60%
EBIT Growth (5y)
58.45%
EBIT to Interest (avg)
9.24
Debt to EBITDA (avg)
2.57
Net Debt to Equity (avg)
0.70
Sales to Capital Employed (avg)
0.86
Tax Ratio
31.64%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
4.92%
ROCE (avg)
9.07%
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
30
Industry P/E
34
Price to Book Value
3.90
EV to EBIT
19.01
EV to EBITDA
18.45
EV to Capital Employed
3.72
EV to Sales
4.82
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
19.57%
ROE (Latest)
12.98%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
RSI
No Signal
Bollinger Bands
Bullish
KST
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Bullish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend13What is working for the Company
PAT(9M)
Higher at Rs 24.26 Cr
NET SALES(Q)
Highest at Rs 55.42 cr
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Anlon Healthcare
Profit After Tax (PAT) - Nine Monthly
At Rs 24.26 cr has Grown at 44.84%
Year on Year (YoY)MOJO Watch
Near term PAT trend is very positive
PAT (Rs Cr)
Net Sales - Quarterly
Highest at Rs 55.42 cr
in the last five quartersMOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Net Sales - Quarterly
At Rs 55.42 cr has Grown at 30.4% (vs previous 4Q average)
over average Net Sales of the previous four quarters of Rs 42.50 CrMOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Profit After Tax (PAT) - Nine Monthly
Higher at Rs 24.26 Cr
than preceding 12 month period ended Mar 2026 of Rs 20.30 crMOJO Watch
In the nine month period the company has already crossed sales of the previous twelve months
PAT (Rs Cr)
